Kolexia
Tredan Olivier Oncologie médicale
Tredan Olivier
Oncologie médicale
Centre Léon-Bérard
Lyon, France
631 Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Métastase tumorale Tumeurs du sein triple-négatives Fatigue Carcinomes Récidive tumorale locale Carcinome épithélial de l'ovaire Obésité

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Perol David
Perol David
Centre Léon-Bérard, Lyon, France
Heudel Pierre Etienne
Heudel Pierre Etienne
Centre Léon-Bérard, Lyon, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Edimark
40 collaboration(s)
Dernière en 2023
MSD
38 collaboration(s)
Dernière en 2023
AstraZeneca
27 collaboration(s)
Dernière en 2023
KEPHREN PUBLISHING
24 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
VRtuose1: VRtuose (Virtual RealiTy and mUsic in the Oncology SEtting) : A Single-centre Feasibility Study Evaluating a Strategy Combining Virtual Reality and Music to Improve Quality of Life in Breast Cancer Patients Undergoing Chemotherapy
Essai Clinique (International Agency for Research on Cancer)   07 mars 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
ESMO open   12 février 2024
BreastImmune03: A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Essai Clinique (Centre Léon-Bérard)   09 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Conférence Santé-Sciences - Olivier TREDAN (Cancérologie) - Facebook
Facebook   06 février 2024
Cancers du sein
Edimark   21 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023